Dr. Savita Prakash
Ph.D.: CEO & President
Dr. Prakash brings more than 15 years of project management experience for both federal agencies and private sector contracts. Dr. Prakash managed several projects for the company. She worked as projects director for 2-phased Criminal Justice Drug Abuse Treatment Studies (CJ-DATS) program funded by National Institutes on Drug Abuse (NIDA-NIH). Dr. Prakash has specialized biomedical management and project coordination experience with DHHS-NIH supported programs. She managed the logistics of collaboration with Northrop Grumman (the prime contractor) and other team partners for the first BRC contract with NIH/NIAID/DMID. She has also served as Principal Investigator/ Project Director on several pharmaceutical and Biotechnology Company projects, including projects from Fortune-50 companies such as Pfizer, where she led the first international market research program for the use of anti-infective drugs in intensive care units (ICUs) across 22 countries. She designed and conducted market research programs for Danippon Pharmaceuticals, Suntory Pharmaceuticals, Innovative Biosensors, and Diversity Programs as well.
Dr. Shiv Srivastava
Ph.D.: Lead Scientific Director
Dr. Shiv Srivastava is an accomplished scientist, a leader and a mentor who has dedicated his professional career focused on cancer science for the benefit of patients. Currently, he contributes to the basic science/translational cancer research as a consultant/advisor to academic/research institutions and biotech/pharma companies. He served as the founding Scientific Director of the Center for Prostate Disease Research (CPDR)/Prostate Cancer Center of Excellence at the Uniformed Services University of the Health Sciences (USUHS) for over 25 years (1993-2018). Along with his commitment with AMAR, he continues to serve the cancer/scientific research community world-wide as a collaborator, mentor, advisory committee member, reviewer for leading journals and funding agencies and as a strong champion for cancer patients.
Dr. Bing Zhang
Ph.D.: Lead Biostatistician
Dr. Zhang has extensive experience in statistics and computer science. He has more than 25 years of experience in line management and statistical analyses for pharmacokinetic (PK), Phase I-IV, and through QTc clinical trials as well as integrated summaries of safety (ISS) and efficacy (ISE) for new drug applications (NDA) in various therapeutic areas (hypertension, pulmonary arterial hypertension, cholesterol lowering, ischemic stroke, anti-viral, pain control, psychotic disorders, oncology, post- operative ileus, blood substitute, etc.). Dr. Zhang specializes in the protocol development support, statistical analysis plans (SAP), and statistical reports; and SAS programming for the generation of CDISC SDTM and ADaM datasets, and interim, final, and exploratory analyses. He serves as a voting member of the Data and Safety Monitory Board (DSMB) for clinical trials and provide statistical support to the DSMB analyses and meetings. In addition, he worked on and/or overseen more than 50 Phase I studies for bioequivalence, bioavailability, PK/PD relationship, PK/QTc relationship, dose-response, dose-escalation, drug interaction, and food effect.
Dr. Rakesh Singh
Dr. Rakesh Singh has over 25 years of extensive experience in climate change, air quality modelling, emission inventory development and analysis of large databases. Rakesh has a PhD degree from the University of Nottingham, UK, a Master’s degree in Environmental Engineering and a Bachelor’s degree in Civil Engineering from MN National Institute of Technology Allahabad, India. He is a registered Professional Engineer in Ontario, Canada. His accomplishments include presenting and publishing over fifty papers in peer-reviewed journals and international conferences. Rakesh is co-founder and President of Lotus Homes Canada Inc., a home building company that provides quality homes to meet customers’ needs, as well as its sister company Lotus Solutions Canada Inc., which provides solutions to climate change and sustainable development related issues.